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Simple Summary: Previous studies reporting large gene panels in breast cancer have mainly reported
on the contribution of additional genes compared to BRCA1/2. We have shown a very large differential
additional effect from non-BRCA genes dependent on a priori likelihood of BRCA1 and BRCA2
combined. We have undertaken panel testing beyond BRCA1/2 in 1398 patients with breast cancer
and identified 95 (6.3%) with actionable breast cancer genes. The highest rate was found for grade 3
ER+ Her2− breast cancers. Those with the lowest likelihood of BRCA1/2 by Manchester score had a
3-fold higher rate of non-BRCA genes whereas those with predicted rates of ~80% had 5-fold higher
rate of BRCA1/2. Unless those referring patients with breast cancer for extended panel testing are
certain there is no loss of sensitivity for BRCA1/2 they should opt of a bespoke BRCA1/2 test first in
those with high prior likelihoods of BRCA1/2 pathogenic variants.
Abstract: Whilst panel testing of an extended group of genes including BRCA1/2 is commonplace,
these studies have not been subdivided by histiotype or by a priori BRCA1/2 probability. Patients
with a breast cancer diagnosis undergoing extended panel testing were assessed for frequency of
actionable variants in breast cancer genes other than BRCA1/2 by histiotype and Manchester score
(MS) to reflect a priori BRCA1/2 likelihood. Rates were adjusted by prior testing for BRCA1/2 in an
extended series. 95/1398 (6.3%) who underwent panel testing were found to be positive for actionable
non-BRCA1/2 breast/ovarian cancer genes (ATM, BARD1, CDH1, CHEK2, PALB2, PTEN, RAD51C,
RAD51D, TP53). As expected, PALB2, CHEK2 and ATM were predominant with 80-(5.3%). The
highest rate occurred in Grade-3 ER+/HER2− breast cancers-(9.6%). Rates of non-BRCA actionable
genes was fairly constant over all likelihoods of BRCA1/2 but adjusted rates were three times higher
with MS < 9 (BRCA1/2 = 1.5%, other = 4.7%), but was only 1.6% compared to 79.3% with MS ≥ 40.
Although rates of detection of non-BRCA actionable genes are relatively constant across BRCA1/2
likelihoods this disguises an overall adjusted low frequency in high-likelihood families which have
been heavily pre-tested for BRCA1/2. Any loss of detection sensitivity for BRCA1/2 actionable variants
in breast cancer panels should lead to bespoke BRCA1/2 testing being conducted first.
Keywords: breast cancer; BRCA1; BRCA2; PALB2; ATM; CHEK2; panel test
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1. Introduction
In recent years there has been a massive expansion in the use of multi-gene panels to
test for breast cancer predisposition. These results have been used as a type of case control
study to assess genes for breast cancer associations and the increase in actionable gene
identification other than BRCA1 and BRCA2 [1–10]. These studies have generally shown
an almost equal rate of pathogenic variants (PVs) identified in BRCA1/2 compared to all of
the additional potentially actionable genes combined. In addition, many of the additional
variants have been identified in the lower penetrance moderate risk genes [11], ATM and
CHEK2, that occur with a higher population prevalence. The only other actionable breast
cancer gene consistently identified at a substantial rate is PALB2, which is now considered
to be a high-risk gene [12]. Many studies have also included a range of organ sites, as well
as including unaffected individuals [2,7–9].
In general, these studies have concentrated on the headline rates of pathogenic vari-
ants (PVs) identified in the additional genes and not on the differential effect of the original
likelihood of a BRCA1/2 pathogenic variant. Most studies that have used a ‘control’ fre-
quency for PVs in the relevant genes have used population databases such as gnomAD [13],
which may not be ideal controls for the population tested as they may not represent the
rates in certain populations especially those with founder effects. We have assessed the
frequency of potentially actionable breast cancer gene variants in a large series of women
with breast cancer comparing rates of detection of non-BRCA PVs with BRCA1/2 at different
BRCA1/2 likelihood scores. We have also assessed the variant frequencies in different breast
pathology subtypes.
2. Materials and Methods
2.1. Study Population
A total of 5060 women with breast cancer and 1443 control samples were included
in the study, male cases were excluded. Of the patients with a breast cancer diagnosis,
4536 were referred to St Mary’s, Wythenshawe and the Christie hospitals in Manchester,
consented and had blood samples taken for DNA extraction testing of breast cancer genes
through the Manchester Centre for Genomic Medicine (MCGM) (Figure 1). MCGM partici-
pants agreed to return of results on genes predisposing to breast cancer. The remaining
participants were recruited through the Predicting the Risk Of Cancer At Screening (PRO-
CAS) study. This study recruited women aged 46–73 years of age from a population
screening programme and included 187 breast cancers diagnosed before study entry and
337 after study entry (total n = 524). In addition, 1443 control samples without breast
cancer from PROCAS [14] were tested as part of Breast Cancer Risk after Diagnostic Gene
Sequencing (BRIDGES). PROCAS women only initially provided consent for return of a
polygenic risk score, but also consented to further research genetic testing. We are applying
for ethical approval to approach women with panel testing to assess whether they wish to
receive results.
2.2. Genetic Testing
Clinical pre-screening for BRCA1/2 variants was carried out on 4142 MCGM patients.
Samples from 874 women were selected for Next Generation Sequencing (NGS) panels,
including 480 who tested negative on BRCA1/2 pre-screening and 394 who had not under-
gone pre-screening. The panel included as a minimum the following genes in addition to
BRCA1 and BRCA2: PALB2, CHEK2, ATM, CDH1, STK11, PTEN, TP53, RAD51C, RAD51D,
BRIP1, BARD1 and NBN. Saliva DNA samples from the PROCAS study [15] were tested as
part of the BRIDGES study utilising a 34 gene panel (ABRAXAS1, AKT1, ATM, BABAM2,
BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, FANCC, FANCM, GEN1, MEN1,
MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PIK3CA, PMS2, PTEN, RAD50,
RAD51C, RAD51D, RECQL, RINT1, STK11, TP53, XRCC2) including the four mismatch
repair (MMR) genes (MLH1, MSH2, MSH6 and PMS2) [16].




Figure 1. Flow chart showing selection of samples for panel testing. 
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Clinical pre-screening for BRCA1/2 variants was carried out on 4142 MCGM patients. 
Samples from 874 women were selected for Next Generation Sequencing (NGS) panels, 
including 480 who tested negative on BRCA1/2 pre-screening and 394 who had not un-
dergone pre-screening. The panel included as a minimum the following genes in addition 
to BRCA1 and BRCA2: PALB2, CHEK2, ATM, CDH1, STK11, PTEN, TP53, RAD51C, 
RAD51D, BRIP1, BARD1 and NBN. Saliva DNA samples from the PROCAS study [15] 
were tested as part of the BRIDGES study utilising a 34 gene panel (ABRAXAS1, AKT1, 
ATM, BABAM2, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, FANCC, 
FANCM, GEN1, MEN1, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, 
PIK3CA, PMS2, PTEN, RAD50, RAD51C, RAD51D, RECQL, RINT1, STK11, TP53, XRCC2) 
including the four mismatch repair (MMR) genes (MLH1, MSH2, MSH6 and PMS2) [16]. 
PVs were annotated according to the ACMG guidelines [17] and verified using 
Sanger sequencing. Additionally, the PV rate of all 5060 women with breast cancer tested 
for BRCA1/2 at the MCGM (1997–2021) and in PROCAS was also assessed, regardless of 
whether they have had (additional) panel testing. The samples clinically tested at MCGM 
were annotated by a clinically approved national laboratory hub. Annotation of research 
results from BRIDGES were initially confirmed by the BRIDGES team and confirmed by 
our in-house research group (EvV). 
2.3. Calculated Likelihood of a BRCA1/1 Pathogenic Variant 
The pathology adjusted Manchester Scoring System (MS) was used to assess likeli-
hoods of a pathogenic variant in BRCA1/2 [18]. Briefly, each breast cancer in a direct line-
age to the index case is scored based on age at diagnosis for each gene (1–6 points) as well 
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PVs were annotated according to the ACMG guidelines [17] and verified using Sanger
sequencing. Additionally, the PV rate of all 5060 women with breast cancer tested for
BRCA1/2 at the MCGM (1997–2021) and in PROCAS was also assessed, regardless of
whether they have had (additional) panel testing. The samples clinically tested at MCGM
were annotated by a clinically approved national laboratory hub. Annotation of research
results from BRIDGES were initially confirmed by the BRIDGES team and confirmed by
our in-house research group (EvV).
2.3. Calculated Likelihood of a BRCA1/1 Pathogenic Variant
The pathology adjusted Manchester Scoring System (MS) was used to assess likeli-
hoods of a pathogenic variant in BRCA1/2 [18]. Briefly, each breast cancer in a direct lineage
to the index case is scored based on age at diagnosis for each gene (1–6 points) as well as
each non mucinous epithelial ovarian cancer (5–8 points). All breast and ovarian cancers
in the index individual are scored with an adjustment for pathology. Her2+, low grade
and lobular cancers receive minus scores for BRCA1 whilst triple negative and high-grade
cancers receive positive scores. Pathology adjusted scores of 15–19 are equivalent to a 10%
probability of a BRCA1/2 pathogenic variant with a 20–24-point score equivalent to a 20%
probability [18]. The proportion of positive tests from panel testing other than BRCA1/2
was adjusted to reflect previous testing of BRCA1/2 and the proportion of p sitive tests
for BRCA1/2 at ch MS score range. Thus a 10% detection rate in BRCA1/2 negative
samples where the BRCA1/2 detection was 50% translates to a 5% overall panel detection
rate beyond BRCA. An actionable breast cancer gene was defined as a gene confirmed in
the BRIDGES stud s having a 2-fold r lative risk for breast cancer [16].
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3. Results
3.1. Participants
A total of 1398 people with breast cancer were included in this study. There were
874 women tested through the MCGM as part of the clinical service or research projects.
Of these, 740 women had a family history of only breast cancer, with 134 having an
additional personal or family history of ovarian cancer. Additionally, 524 affected women
and 1443 female controls that took part in the PROCAS study were included (age range
29–75; median 58.8 years) and were tested as part of the BRIDGES study (Figure 1).
Overall, 480 women with a family history (34.3%) and MS of −1 (some score below
0 with pathology adjustment) up to 56 (median 18) had been negative for BRCA1/2 on
a pre-screen.
All panels included the following genes: PALB2, CHEK2, ATM, CDH1, STK11, PTEN,
TP53, RAD51C, RAD51D, BRIP1, BARD1 and NBN. All 524 population-based samples and
347 familial samples (total n = 871) were also tested for variants in mismatch repair (MMR)
genes. In addition, 1443 controls without breast cancer from PROCAS aged 46–73 years
were tested for the full panel, including MMR genes.
Additionally, the PV status of all 5060 women with breast cancer tested for BRCA1/2
was included in order to determine the effect of extended panel testing in women stratified
by MS.
3.2. Pathogenic Variant Rate
Overall, 174/1398 (12.4%) PVs were identified in 172 women (BRCA1 (26); BRCA2 (43);
ATM (31); BARD1 (1); BRIP1 (7); CDH1 (1); CHEK2 (25); NBN (3); PALB2 (24); PTEN (1);
RAD51C (1); RAD51D (1); TP53 (10)) (Table 1). One woman harboured both a BRCA1 and a
BRCA2 PV and one woman carried a BRCA2 PV as well as a BRIP1 PV.
Of the 874 women tested via MCGM, 60 BRCA1/2 PVs were identified in 59 women
(BRCA1 (25); BRCA2 (35) (one harboured both a BRCA1 and a BRCA2 PV), however
480 samples had already screened negative for BRCA1/2. This thus represents a detection
rate of 60/394 (15%). In the remaining 815 women, 80 PVs were identified in non-BRCA1/2
genes (ATM (25); BARD1 (1); BRIP1 (5); CDH1 (1); CHEK2 (15); NBN (2); PALB2 (20);
RAD51C (1); RAD51D (1); TP53 (9)).
Of the 524 women recruited through PROCAS, 34 PVs in 33 women were identified
(BRCA2 (8); BRCA1 (1); ATM (6); BRIP1 (2); CHEK2 (10); NBN (1); PALB2 (4); PTEN (1);
TP53 (1); one woman harboured both a BRCA2 and a BRIP1 PV).
A total of 95 of 1398 (6.3%) women who underwent panel testing were found to be
positive for actionable non-BRCA1/2 breast/ovarian cancer genes (ATM, BARD1, CDH1,
CHEK2, PALB2, PTEN, RAD51C, RAD51D, TP53). As expected, PALB2, CHEK2 and ATM
were the most frequent with 80 (5.3%) PVs accounting for 84.2% non BRCA1/2 actionable
results. Of the other high-risk genes there were 10 TP53, one CDH1 and one PTEN PVs,
but none in STK11. All the expected breast cancer associated genes (ATM, CHEK2, PALB2,
TP53) had significantly increased odds ratios of above 2-fold compared to the 1443 PRO-
CAS control samples (Table 1). Other PVs were identified in genes that have a less clear
association with breast cancer such as: BRIP1, NBN, RAD50 and RECQL, but none of these
showed significant associations.
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Table 1. Rates of detection of BRCA1/2 and non BRCA breast/ovarian pathogenic variants by Manchester score.
Manchester Score ≤8 9–10 11–12 13–14 15–19 20–24 25–29 30–39 ≥40 Total PVs Cases PROCAS Controls PVs OR 95% CI p-Value
Full extended panel cohort
BRCA1 1 0 0 0 2 3 3 9 8 26 2 NA NA NA
BRCA2 5 1 1 4 11 4 9 7 1 43 6 NA NA NA
ATM 7 2 1 3 7 5 3 3 0 31 5 6.52 2.56–15.55 <0.0001
CHEK2 12 0 1 2 4 2 0 3 1 25 3 8.74 2.88–27.60 <0.0001
TP53 * 3 0 0 0 4 1 1 0 1 10 0 36.02 6.33–392.1 <0.0001
PALB2 2 3 3 1 6 6 3 0 0 24 3 8.38 2.74–26.53 <0.0001
NBN 1 1 0 0 1 0 0 0 0 3 2 1.55 0.32–8.75 0.6825
CDH1 0 0 0 1 0 0 0 0 0 1 0 n/a
RAD51C 0 0 0 0 0 0 1 0 0 1 0 n/a
RAD51D 0 0 0 0 0 0 1 0 0 1 0 n/a
BRIP1 1 0 0 2 1 3 0 0 0 7 2 3.63 0.82–17.31 0.1037
BARD1 1 0 0 0 0 0 0 0 0 1 1 1.03 0.05–19.62 >0.9999
PTEN 1 0 0 0 0 0 0 0 0 1 0 n/a
Total PVs 34 7 6 13 36 24 21 22 11 174 24
Total tested 525 78 91 106 255 149 95 72 27 1398 1443
% PVs 6.5% 9.0% 6.6% 12.3% 14.1% 16.1% 22.1% 30.6% 40.7% 12.4% 1.7%
Total non-BRCA PVs 28 6 5 9 23 17 9 6 2 105
% non-BRCA PVs 5.3% 7.7% 5.5% 8.5% 9.0% 11.4% 9.5% 8.3% 7.4% 7.5%
% adjusted for all
BRCA1/2 tested 5.3% 7.4% 5.3% 8.0% 8.1% 8.8% 6.4% 3.6% 1.5% 6.4%
No pre-screen
BRCA1 1 0 0 0 2 3 3 9 8 26 2 21.00 5.41–90.02 <0.0001
BRCA2 5 1 1 4 11 4 9 7 1 43 6 11.77 5.05–25.65 <0.0001
ATM 6 2 0 3 3 3 1 1 0 19 5 6.08 2.43–14.96 <0.0001
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Table 1. Cont.
Manchester Score ≤8 9–10 11–12 13–14 15–19 20–24 25–29 30–39 ≥40 Total PVs Cases PROCAS Controls PVs OR 95% CI p-Value
CHEK2 12 0 0 0 0 0 0 1 0 13 3 6.89 2.04–22.80 0.001
TP53 * 2 0 0 0 0 0 0 0 0 2 0 10.91 1.27–158.2 0.0647
PALB2 2 3 0 0 3 3 2 0 0 13 3 6.89 2.04–22.80 0.001
NBN 1 1 0 0 0 0 0 0 0 2 2 1.57 0.25–10.06 0.6448
CDH1 0 0 0 1 0 0 0 0 0 1 0 n/a
RAD51C 0 0 0 0 0 0 0 0 0 0 0 n/a
RAD51D 0 0 0 0 0 0 0 0 0 0 0 n/a
BRIP1 1 0 0 2 0 2 0 0 0 5 2 3.95 0.85–19.9 0.1172
BARD1 1 0 0 0 0 0 0 0 0 1 1 1.57 0.08–29.9 >0.9999
PTEN 1 0 0 0 0 0 0 0 0 1 0 n/a
Total PVs 32 7 1 10 19 15 15 18 9 126 24
Total tested 487 66 63 53 108 59 37 33 12 918 1443
% PVs 6.6% 10.6% 1.6% 18.9% 17.6% 25.4% 40.5% 54.5% 75.0% 13.7% 1.7%
Total non-BRCA PVs 26 6 0 6 6 8 3 2 0 57
% non-BRCA PVs 5.3% 9.1% 0.0% 11.3% 5.6% 13.6% 8.1% 6.1% 0.0% 6.2%
% BRCA1/2 PVs 1.2% 1.5% 1.6% 7.5% 12.0% 11.9% 32.4% 48.5% 75.0% 7.5%
% adjusted for all
BRCA1/2 tested 5.3% 8.8% 0.0% 10.6% 5.0% 10.4% 5.5% 2.6% 0.0% 5.3%
Negative pre-screen
ATM 1 0 1 0 4 2 2 2 0 12 5 7.4 2.7–19.0 <0.0001
CHEK2 0 0 1 2 4 2 0 2 1 12 3 12.3 3.5–41.0 <0.0001
TP53 * 1 0 0 0 4 1 1 0 1 8 0 84.7 13.2–941.5 <0.0001
PALB2 0 0 3 1 3 3 1 0 0 11 3 11.3 3.5–37.9 <0.0001
NBN 0 0 0 0 1 0 0 0 0 1 2 1.50 0.1–12.9 0.5777
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Table 1. Cont.
Manchester Score ≤8 9–10 11–12 13–14 15–19 20–24 25–29 30–39 ≥40 Total PVs Cases PROCAS Controls PVs OR 95% CI p-Value
CDH1 0 0 0 0 0 0 0 0 0 0 0 n/a
RAD51C 0 0 0 0 0 0 1 0 0 1 0 n/a
RAD51D 0 0 0 0 0 0 1 0 0 1 0 n/a
BRIP1 0 0 0 0 1 1 0 0 0 2 2 3.02 0.5–19.3 0.261
BARD1 0 0 0 0 0 0 0 0 0 0 1 n/a
PTEN 0 0 0 0 0 0 0 0 0 0 0 n/a
Total PVs 2 0 5 3 17 9 6 4 2 48 16
Total tested 38 12 28 53 147 90 58 39 15 480 1443
% PVs 5.3% 0.0% 17.9% 5.7% 11.6% 10.0% 10.3% 10.3% 13.3% 10.0% 1.1%
% adjusted for all
BRCA1/2 tested 5.2% 0.0% 17.1% 5.3% 10.3% 7.7% 7.0% 4.5% 2.8% 8.5%
All samples tested for BRCA1/2
BRCA1 4 5 5 16 49 87 60 94 67 387
BRCA2 9 7 15 22 82 86 66 65 25 377
Total tested 878 326 468 619 1240 745 387 281 116 5060
% BRCA1/2 PVs 1.5% 3.7% 4.3% 6.1% 10.6% 23.2% 32.6% 56.6% 79.3% 15.1%
* Population frequency estimate for local population taken as 1 in 5000; NA-Not assessable as 480 pre-screened for BRCA1/2.
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3.3. Detection Rate by Manchester Score
The detection rates of PVs in non-BRCA1/2 genes in the full extended panel cohort did
not vary substantially by MS (ranging between 5.3–11.4%). However, when controlling for
those with prior BRCA1/2 testing, the added value of the extended panel was actually lower
in those with a higher MS (i.e., those individuals with a higher probability of a BRCA1/2
pathogenic variant). Only 2.97% of those with MS ≥ 30 tested positive for a non-BRCA1/2
PV when allowing for the higher likelihood of a BRCA1/2 positive result of 63.2% (251/397)
in the group of all individuals tested for BRCA PVs.
There was no significant difference between rates of the most commonly detected
non-BRCA PVs in those with MS ≥ 15 and <15 (ATM PVs (3.0% and 1.6% p = 0.098), CHEK2
PVs (1.7% and 1.9% p = 0.84) and PALB2 PVs (2.5% and 1.1% p = 0.0605)). Although the
combined total of all PVs in all three genes with MS ≥ 15 was statistically significantly
higher at 7.2% (43/598) vs. 4.6% (37/800)-p = 0.05 this did not take into account pre-
screening for BRCA1/2.
Of all women tested for BRCA1/2 PVs (n = 5060), 764 (15.10%) harboured a PV in
BRCA1/BRCA2 (Table 1). In this group, 92/116 (79.3%) women with breast cancer and a MS
of ≥40 tested positive for a BRCA1/2 PV (BRCA1 (n = 67) or BRCA2 (n = 25)). In the study
cohort, only an additional two non-BRCA PVs were identified in the group of women with
a MS ≥ 40 (2/15 (13.3%) and a negative pre-screen). The adjusted proportion of PVs in
non-BRCA genes of 75/1204 (6.2%) for MS ≤ 10 was significantly higher than for those
with scores ≥30 (12/405-3.0%-p = 0.01).
Of the 918 women in the study cohort without pre-screening, 68 (7.4%) tested positive
for PVs in BRCA1 (n = 25), BRCA2 (n = 42) or both (n = 1). There was an increase in
BRCA1/2 PV detection rate with increasing MS, similar to the 5060 women tested only for
BRCA1/2 PVs.
Of the 871 women tested for variants in the MMR genes, very few PVs were identified.
There were only two cases with an MSH6 PV (Supplementary Table S1). No PVs in MLH1
or MSH2 were identified. Similarly, in the control group there was only one MSH6 and one
MSH2 PV identified.
Only 9/524 (1.7%) population-based PROCAS samples tested positive for a BRCA1/2
PV (MS: 0–33 median = 3, BRCA1 (n = 1), BRCA2 (n = 8)). Only 28/524 samples met the
MS ≥ 15 score (indicating a 10% threshold was met) and only 2/28 (7.1%) had a BRCA1/2
PV (BRCA1 = 1, BRCA2 = 1). However, two women in this group had a PALB2 PV. In those
who did not meet the 10% threshold (MS < 15), there were 7/496 (1.4%) BRCA1/2 PVs
detected. In familial samples, 37/124 (29.8%) with MS ≥ 20, 11/91 (12.1%) with MS 15–19
and 5/173 (2.9%) with MS < 15 testing positive for BRCA1/2.
A total of 134 women with breast cancer had either a personal (n = 25) or family
history (n = 109) of ovarian cancer. Detection rates were similar to those with breast cancer
only with 8/134 (6%) having a PV beyond BRCA1/2 (PALB2 = 2) and 2/25 (8%) with breast
and ovarian double primaries (Supplementary Tables S2 and S3).
3.4. Detection Rate by Tumour Pathology
Breast cancer cases with tumour pathology reports, including human epidermal
growth factor receptor 2 (HER2) status are presented in Table 2. The lowest overall detection
rate (6.1%). for any PV, including BRCA1/2, was in grade 1 estrogen receptor (ER)+/HER2−
breast cancers. The highest detection rates were in grade 3 ER+/HER2− (18.7%) and triple
negative cases (17.5%).
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Table 2. Rate of PVs by pathology and Manchester score.
All Patients Tested for BRCA1/2 PVs (n = 5060) Patients Included for Panel Testing (n = 1398)







Lobular total 4 1.2% 19 5.6% 341 6.74% 11 8.6% 128 7.8% ATM(4), BRCA2(1), CDH1(1), CHEK2 (1), TP53(1),PALB2(3)
Lobular MSS ≥ 20 2 2.7% 8 10.7% 75 13.3% 5 11.9% 42 11.9% ATM(2), TP53 (1), PALB2(2)
Lobular MSS < 20 2 0.75% 11 4.1% 266 4.9% 6 6.98% 86 5.8% ATM(2), BRCA2(1), CDH1(1), CHEK2(1), PALB2(1)
Grade 1 total 3 0.8% 12 3.3% 363 4.1% 8 6.1% 132 4.55% ATM(2), BRCA2(2), BRIP1(2), CHEK2(1), TP53(1)
Grade 1 MSS ≥ 20 3 4.8% 3 4.7% 63 9.5% 1 6.7% 15 6.7% BRIP1(1)
Grade 1 MSS < 20 0 0.0% 9 3.0% 300 3.0% 7 5.98% 117 4.3% ATM(2), BRCA2(2), BRIP1(1), CHEK2(1), TP53(1)
IDC Grade 2 ER+
total 10 1.3% 70 9.2% 763 10.5% 23 8.98% 256 4.3%
ATM(6), BRCA2(13), BRIP1(1), CHEK2(2), PALB2(1),
RAD51C(1)
IDC Grade 2 ER+
MSS ≥ 20 8 4.3% 38 20.5% 185 24.8% 13 25.5% 51 7.8% ATM(2), BRCA2(9), PALB2(1), RAD51C(1)
IDC Grade 2 ER+
MSS < 20 2 0.35% 32 5.5% 578 5.9% 10 4.9% 205 3.4% ATM(4), BRCA2(3), BRIP1(1), CHEK2(2)
IDC Grade 3 ER+
total 43 8.4% 74 14.4% 513 22.8% 28 18.7% 150 10.0%
ATM(4), BRCA1(6), BRCA1&BRCA2(1), BRCA2(6),
CHEK2(3), PALB2(5), RAD51D(1), TP53(2)
IDC Grade 3 ER+




IDC Grade 3 ER+
MSS < 20 9 2.85% 20 6.33% 316 9.2% 11 10.4% 106 7.55% ATM(2), BRCA2(3), CHEK2(2), PALB2(3), TP53(1)
TNT total 199 20.35% 61 6.24% 978 26.6% 31 17.5% 177 7.3% ATM(1), BRCA1(14), BRCA2(4), BARD1(1),BRIP1(1), CHEK2(2), PALB2(7), RECQL(1)
TNT MSS ≥ 20 158 33.40% 46 9.73% 473 43.1% 19 24.4% 78 6.4% BRCA1(12), BRCA2(2), BRIP1(1), CHEK2(1),PALB2(3)
TNT MSS < 20 41 8.12% 15 2.97% 505 11.1% 12 12.1% 99 8.1% ATM(1), BRCA1(2), BRCA2(2), BARD1(1),CHEK2(1), PALB2(4), RECQL(1)
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Table 2. Cont.
All Patients Tested for BRCA1/2 PVs (n = 5060) Patients Included for Panel Testing (n = 1398)







HER2+ total 5 1.72% 13 4.5% 290 6.2% 10 9.8% 102 7.8% ATM(3), BRCA2(2), CHEK2(1), PALB2(1), TP53(3)
HER2+ MSS ≥ 20 2 4.88% 3 7.3% 41 12.2% 1 8.3% 12 8.3% PALB2(1)
HER2+ MSS < 20 3 1.20% 10 4.2% 249 5.2% 9 10.0% 90 7.8% ATM(3), BRCA2(2), CHEK2(1), TP53(3)
DCIS total 8 2.80% 22 7.7% 286 10.5% 18 15.25% 118 9.3% ATM(4), BRCA2(7), BRIP1(1), CHEK2(3), PALB2(2),TP53(1)
DCIS MSS ≥ 20 4 7.55% 11 20.75% 53 28.3% 5 33.3% 15 13.3% ATM(1), BRCA2(3), TP53(1)
DCIS MSS < 20 4 1.72% 11 4.7% 233 6.4% 13 12.6% 103 8.7% ATM(3), BRCA2(4), BRIP1(1), CHEK2(3), PALB2(2)
NOS total 115 7.54% 106 6.95% 1526 14.5% 41 12.2% 335 8.4% ATM(7), BRCA1(5), BRCA2(8), BRIP1(1),CHEK2(12), PALB2(5), PTEN(1), TP53(2)
NOS MSS ≥ 20 97 21.95% 79 17.9% 442 39.8% 16 18.6% 86 10.5% ATM(4), BRCA1(4), BRCA2(3), BRIP1(1), CHEK2(4)
NOS MSS < 20 18 1.66% 27 2.5% 1084 4.15% 25 10.0% 249 7.6% ATM(3), BRCA1(1), BRCA2(5), CHEK2(8), PALB2(5),PTEN(1), TP53(2)
Total overall 387 7.65% 377 7.45% 5060 15.1% 170 12.2% 1398 7.3%
ATM(31), BRCA1(25),
BRCA2(42),BRCA1&BRCA2(1), BARD1(1), BRIP1(6),
CDH1(1), CHEK2(25), PALB2(24), PTEN(1),
TP53(10), RAD51C (1), RAD51D(1), RECQL(1)
MSS ≥ 20 308 20.14% 242 15.8% 1529 35.9% 77 22.45% 343 9.9%
ATM (11), BRCA1(22), BRCA2(20),
BRCA1&BRCA2(1), BRIP1(3), CHEK2(6), PALB2(9),
TP53(3), RAD51C (1), RAD51D(1)
MSS < 20 79 2.24% 135 3.8% 3531 6.1% 93 8.8% 1055 6.4%
ATM (20), BRCA1(3), BRCA2(22), BARD1(1),
BRIP1(3), CDH1(1), CHEK2(19), PALB2(15),
PTEN(1), TP53(7), RECQL(1)
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4. Discussion
The present study has confirmed some utility for breast cancer gene panels extended
beyond BRCA1/2 in women with breast cancer. Nonetheless, the increased diagnostic
yield is dominated by just three additional genes (PALB2, ATM and CHEK2) accounting
for over 80% of non-BRCA1/2 variants found. Additionally, although BRCA1/2 pre-testing
increases the rate of pathogenic variant detection in these genes, with higher familial scores
represented by the MS, the added benefit from a panel is lower when adjusting for a higher
likelihood of BRCA1 and BRCA2 PVs. For instance, an index case with a MS ≥ 40 would
have an ~80% chance of a BRCA1/2 PV, but only a 1–2% chance of a PV in another actionable
gene. In contrast, with a MS ≤ 8 there is only around a 1% chance of a BRCA1/2 PV, but a
5% chance of finding another PV (mainly in ATM or CHEK2). Previous studies have not
addressed this large differential effect. For those with a very high likelihood of a BRCA1/2
PV by an accepted method (MS, BOADICEA/CANRISK, BRCAPRO), any loss in sensitivity
of identification of a BRCA1/2 PV would mitigate any additional benefit from an extended
panel vs. a targeted BRCA1/2 approach. Some loss of sensitivity is accepted in most panel
tests but even a drop by 2% for a family with a MS ≥ 40 would be sufficient to warrant
bespoke BRCA1/2 testing as the first test. Although most NGS panels claim to identify large
single or multiple exon copy number variations (CNVs), the proven sensitivity of these
tests is less clear. In Manchester, 20% of non-Jewish BRCA1 PVs are CNVs that in the past
have been detected by multiple ligation-dependent probe amplification (MLPA). Given that
any additional gene identified is likely to have lower penetrance than BRCA1 or BRCA2
e.g., in a large family with multiple breast/ovarian cancer cases (MS ≥ 40), it is unlikely
that this will be the entire explanation for the pattern observed. For instance we observed a
RAD51C PV in a large breast/ovary family which probably only fully explains the ovarian
cancer predisposition [19], and for the ATM and CHEK2 variants in six families with MS
of 30–39 and one CHEK2 in a MS of >40, these are unlikely to provide a full explanation
for the pattern of disease in these families (Table 1) [11]. We have previously shown that
a pathogenic RAD51D variant in a family with three women with ovarian cancer and
four with breast cancer(MS = 55) fully segregated with disease and that BRCA1/2 testing,
including RNA analysis was negative [19]. Given that only a two-fold increased likelihood
of breast cancer is associated with RAD51D PVs, it is still unlikely that RAD51D fully
explains the breast cancer risk in this family, although polygenic risk could add somewhat
to the effects of RAD51D. Although results from BRIDGES [16] and other studies clearly
differentiate PALB2 as a high-risk gene and CHEK2 as moderate-risk, this is not reflected in
the similar ORs for CHEK2 and PALB2 of around eight-fold, but these risk estimates have
large confidence intervals due to the small number of controls with identified variants and
are based on testing many familial families with pre-screens of BRCA1/2.
Case control analysis is arguably the most informative method to identify breast
cancer gene associations as it also provides confirmation of the level of any increased risk.
Many recent large-scale studies have published regarding this, including recent evidence
that variants in the MMR genes MSH6 and PMS2 may be associated with an increased risk
of breast cancer [2,20]. Although the first of these studies was a true case control study,
there has been concern that one of the variant calls in MSH6 (c.2945delC; p.(Pro982Leufs))
that was very frequent in cases, may be spurious due to a sequencing artifact [21]. This
study also used gnomAD controls [13] rather than a matched, local population control
series. The second study was not a true case control study and assessed risk in carriers
identified on panel testing without adjusting for the proportion of referred cases with
breast cancer [20]. The very high population frequencies of variants in MSH6 and PMS2
without typical Lynch syndrome associated cancers may ironically have falsely elevated
the odds ratio [22]. Furthermore, no evidence for any association between these variants in
MMR genes and breast cancer has been seen in larger case control studies [1], segregation
analysis [23], nor in prospective analysis of PV carriers [24], with the possible exception
of MSH6 in BRIDGES, which was borderline significant at two-fold risk [16]. As such,
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patients with MMR PVs, with the possible exception of MSH6, should not be advised that
they are at increased risk of breast cancer.
The lowest detection rate overall both for BRCA1/2 and additional panel genes was
for grade 1 cancers with 4.1% and 4.5% respectively. The highest detection rate was for
grade 3 ER+ HER2− breast cancers with a non BRCA1/2 panel detection rate of 10%. There
has been very little in the literature on the effect of pathology on panel detection rates in
non-BRCA1/2 genes although we have recently reported an association with PALB2 and
grade 3 [25]. A Brazilian study recently also confirmed a higher detection rate in high
grade tumours [26]. Although this was a small study (n = 224; 61 PVs-19 BRCA1/2) and the
association was likely driven primarily by BRCA1/2. The BRIDGES study did not assess
grade, but there was a clear association between RAD51C, RAD51D, PALB2 and BARD1,
with ER− breast cancer and ATM and CHEK2 with ER+ breast cancer with no association
of ATM with ER− [16].
The present study does have some limitations. The size of the control population was
probably not large enough to generate very reliable odds ratio estimates. We had to use our
previous population estimate for TP53 [27], but had no such estimate for other rare genes
such as CDH1. The study was not large enough to statistically assert that BRIP1 is not an
actionable breast cancer gene [28]. Nor was it large enough to address the variant detection
rates for the ovarian susceptibility genes RAD51C and RAD51D that have previously
been excluded as breast cancer susceptibility genes [29,30], but which were more recently
confirmed as breast cancer genes just reaching two-fold relative risk [16]. There is also
some previous evidence that variants in RAD51D may predispose specifically to triple
negative breast cancer [16]. The BRIDGES study also only called definitive PVs using NGS
and did not call CNVs. As already stated, this could have reduced PV detection sensitivity
in the UK population to below 80% for BRCA1. The odds ratios for BRCA1 could therefore
be exaggerated by the fact that in-house testing of over 4536 cases in Table 1 included
MLPA, since CNVs were not reported in the control samples tested in the BRIDGES study.
Despite this, our study also has a number of strengths. This is a large study with well
documented family history, including first and second-degree relatives. A high proportion
of the study patients had full pathology available, including HER2 status, which was not
generally available before 2000. We have also used matching local controls known not to
have breast cancer.
5. Conclusions
Although the trend towards panel testing beyond BRCA1/2 is likely to be irreversible,
there are some lessons to be learnt from the current study. The majority of the increased
diagnostic yield results from just three genes PALB2, CHEK2 and ATM. Only PALB2 can
be considered a strong enough risk factor on its own and the actionability of ATM and
CHEK2 pathogenic variants needs to be taken in the context of other risk factors, including
a polygenic risk score, ideally through a validated model such as BOADICEA/CanRisk [31].
Women with certain tumours, and in particular grade 1 invasive breast cancers, should
be informed that there is a very low likelihood of any meaningful result from panel
testing. Finally, the low adjusted diagnostic uplift in those with very high a priori likelihood
of BRCA1/2 means that clinicians should ensure that panels used have high sensitivity
for BRCA1/2 PVs present in their population or opt for bespoke BRCA1/2 testing in the
first instance.
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